138 related articles for article (PubMed ID: 32800493)
1. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
Bekes I; Eichler M; Singer S; Friedl TWP; Harbeck N; Rack B; Forstbauer H; Dannecker C; Huober J; Kiechle M; Lato K; Janni W; Fink V
Clin Breast Cancer; 2020 Dec; 20(6):439-447. PubMed ID: 32800493
[TBL] [Abstract][Full Text] [Related]
2. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
4. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L; Harbeck N; Singer S; Eichler M; Rack B; Forstbauer H; Wischnik A; Scholz C; Huober J; Friedl TW; Weissenbacher T; Härtl K; Kiechle M; Janni W; Fink V
Breast; 2016 Jun; 27():69-77. PubMed ID: 27054751
[TBL] [Abstract][Full Text] [Related]
5. Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma.
Filip S; Vanásek J; Bláha M; Vávrová J
Neoplasma; 1997; 44(4):212-8. PubMed ID: 9473775
[TBL] [Abstract][Full Text] [Related]
6. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
8. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Mutschler NS; Scholz C; Friedl TWP; Zwingers T; Fasching PA; Beckmann MW; Fehm T; Mohrmann S; Salmen J; Ziegler C; Jäger B; Widschwendter P; de Gregorio N; Schochter F; Mahner S; Harbeck N; Weissenbacher T; Jückstock J; Janni W; Rack B
Clin Breast Cancer; 2018 Apr; 18(2):175-183. PubMed ID: 29598955
[TBL] [Abstract][Full Text] [Related]
11. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
[TBL] [Abstract][Full Text] [Related]
12. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
13. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Hepp P; Fasching PA; Beckmann MW; Fehm T; Salmen J; Hagenbeck C; Jäger B; Widschwendter P; de Gregorio N; Schochter F; Mahner S; Harbeck N; Weissenbacher T; Kurt AG; Friedl TWP; Janni W; Rack B
Clin Breast Cancer; 2018 Oct; 18(5):e1103-e1110. PubMed ID: 30017795
[TBL] [Abstract][Full Text] [Related]
14. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
16. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
17. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
[TBL] [Abstract][Full Text] [Related]
18. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
19. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
Papakonstantinou A; Hedayati E; Hellström M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Acta Oncol; 2020 Jan; 59(1):75-81. PubMed ID: 31583943
[No Abstract] [Full Text] [Related]
20. Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis.
Lee J; Ahn MH; Jang YH; Lee EJ; Park JH; Rho J; Kim Z; Kim HM; Han SW; Lim C; Lee MH; Kim SY
Breast Cancer; 2014 Nov; 21(6):670-6. PubMed ID: 23371824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
